CeBiB Chile

The Center for Biotechnology and Bioengineering is created in 2014, after being selected by the Research Partnership Program of CONICYT to be part of the national program for Basal Funding for Excellence Scientific and Technological Centers.

CeBiB is a Centre of Excellence in cutting-edge research composed by an interdisciplinarian team of renowned national and international scientits, capable of investigating key aspects and current trens in biotechnology and bioengineering, including the research for important applications for industry.

One of the main goals of CeBiB is the research and development of applications to be used in areas where Chile has significant comparative advantages, looking for these areas always in line with the interests of the industry and the needs of the public and private sectors, to increase the competitiveness of the national economy based on scientific and technological innovation.

CeBiB is composed by researchers and academics leaders in their fields from Chilean universities: Universidad de ChileUniversidad de AntofagastaUniversidad de Santiago de ChileUniversidad de La Frontera and Universidad de Los Lagos.

Website:
www.cebib.cl/en/
Diagnostics Subsector
Year Founded
2014
MarĂ­a Isabel Guerra
Dr. Daniela Vaisman
LinkedIn logo Project Engineer 
BIO

Civil engineer in biotechnology, bilingual and graduated from postgraduate programs in the areas of chemistry and biotechnology. Positive, proactive and efficient, with great interest in learning about new areas. With a productive career, focused primarily on biotechnology and the chemical industry; management and innovation, related with the postgraduate studies and with independent projects (production of hyaluronic acid from bacteria; optimization microorganisms cultures; development of a ELISA Kit for salmon; collagen extraction from cuttlefish; Lobesia botrana trap and repellent, CORFO Projects, HibridaLab, Hospital SCM, etc.). A particular training in innovation and entrepreneurship in the last years has allowed to develop the ability to work guiding different interdisciplinary groups, mainly associated with emerging projects and structuring business models. With special interest in the formulation and development of innovation projects within and outside companies, particularly related with the biotechnology industry, health and process engineering.

Chinese University of Hong Kong Hong Kong SAR China

As one of the top universities in Asia-Pacific, The Chinese University of Hong Kong (CUHK) is committed to knowledge transfer and seeks to foster partnerships to commercialise our university’s technologies in the best way to benefit both industry and society. In this regard, CUHK is continuously looking for potential partners/licensees in our below areas of biomedical technologies:

 

(1)   Therapeutics: Digestive Cancer / Diabetes / Liver Cancer / Neurological Disorders / Orthopaedic and Traumatological Disorders / Pluripotent Stem Cells (see https://goo.gl/Ozm5Gz)

(2)   Diagnostics: Cardiovascular Disorders / Digestive Cancers / Diabetes & its Comorbidities / Gynecology and Obstetrics / Orthopaedic & Traumatological Disorders / Wearables (see https://goo.gl/gcbdLF)

(3) Robotics: Surgical Robots / Endoscopes for Minimally Invasive Surgery and Diagnostic Purposes (see https://goo.gl/TrQSrz

Dr. Ken YC Chow
Dr. Ken YC Chow
Technology Liaison Officer 
BIO

Prof. Edwin CHAN from the School Life Sciences from the Chinese University of Hong Kong is working on rare neurodegenerative diseases including the Huntington’s Disease (HD). He recently developed a new inhibitor for the treatment of HD. This patented technology is known as P3. P3 is a 13-amino acid peptidylic inhibitor that can potently suppress expanded Polyglutamine (PolyQ) / CAG RNA-induced nucleolar stress, and rescue neurodegeneration in animal disease model and cell death in patient fibroblasts.

 

The core benefits of this technology are:

(1)   the inhibitor is capable of directly interacting with and neutralizing the toxic expanded PolyQ / CAG RNA,

(2)   the mechanism of this inhibitor is well-defined that it reduces cellular p53 level and suppresses caspase activities, and

(3)   with proven potential to treat other polyglutamine diseases, such as spinocerebellar ataxias (SCA).

 

Related patent and references:

(1)   Zhang et al, Dis. Model. Mech, 2016 (http://www.ncbi.nlm.nih.gov/pubmed/26839389)

(2)   Tsoi et al, PNAS, 2012 (http://www.ncbi.nlm.nih.gov/pubmed/22847428)

(3)   US9,297,798 (http://www.google.com/patents/US9297798)

(4)   US Provisional patent (Priority date: 23 Dec 2015)

(5)   US non-Provisional patent (Priority date: 17 Feb 2016)

 

More details:

(1)   Introduction Slides: http://goo.gl/RSZf7g

(2)   Introduction Brochure: http://goo.gl/IdbVRG

(3)  Introduction Videos: https://goo.gl/nfZAbK

KOTRA United States

Korea Trade Investment Promotion Agency, otherwise known as KOTRA, operates under South Korea's Ministry of Trade, Industry & Energy (MOTIE), as the national trade and investment promotion organization.  KOTRA is a governmental, non-profit agency which promotes and facilitates bilateral business relationships between Korea and the world since its foundation in 1962.

Since inception, KOTRA has facilitated Korea's rapid, export-led economic development through various trade promotion activities such as SME export promotion, trade info services, government-to-government export, foreign investment in Korea (FDI) promotion, and business matchmaking. KOTRA maintains over 120 offices in 82 countries with 13 in South Korea alone. 

I am currently co-leading North America's Startup GP program. A collaboration project between KOTRA's Global Partnering and Overseas Startup Assistance Program. This effort is a part of Korean President Park Geun-hye's "Creative Economy" policy designed to help promising Korean startups connect with leading Corporate Venture Capital firms in the US for potential partnership and investment opportunities.

Lastly, I am the Head of Medical GP. Connect US based Medical and Pharmaceutical companies with Korean counterparts and implement R&D projects, which are co-funded by the Korean government, and I.P. licensing. 

Benjamin Brand
Benjamin Brand